Meridian launches Epstein-Barr tests:
This article was originally published in Clinica
Meridian Bioscience has launched two tests for Epstein-Barr virus (EBV), TRU EBV-M and TRU EBV-G, in Europe, including Scandinavia. The tests, which were approved there in late March, are the first on the market using recombinant antigen technology to detect immunoglobulin (Ig)M and IgG antibodies specific to EBV, the Cincinnati, Ohio-based firm claimed. EBV causes infectious mononucleosis, or glandular fever, and current glandular fever diagnostics rely primarily on the patient's symptoms and non-specific antibody testing, Meridian said. CEO Jack Kraeutler said the firm would monitor the products' success in Europe before deciding whether to file them in the US.